We want to transform unique innovations and technologies into excellent businesses in the health care sector.
- Why life science? The accelerating need for health care services is met by tremendous efforts in research and development from both the governmental and private sectors. New innovative technologies in life science are being developed with high speed. People with medical and health care needs will increasingly benefit from new and improved treatment options. New treatment options create improved quality of life and reduced mortality for people around the world. Our focus is to identify great entrepreneurs and companies with unique technologies with the potential to bring new important health care services to the life science market. By partnering up with entrepreneurs as well as co-investors, we can exploit the market potential offered by new technologies.
Birk Venture has a long term and flexible investment approach. We can invest in life science companies in an early stage as well as companies in more developed stage.
We want to build a diversified portfolio of companies in the life science sector. There are some important characteristics and elements that needs to be in place before we invest in a company:
|Medical devices and instruments|
Birk Venture has a rich deal flow. Our deal flow is coming from various sources such as Universities, start-ups or spin-offs from private sector and from co-investors (Private Investment Consortium).
Hans Ivar has 21 years professional experience in the Pharmaceutical and Biotech industry including 4 years with capital investments in life science. He has held several leading international positions in AstraZeneca, Pfizer and Pronova BioPharma. His experience covers a broad specter within the pharmaceutical and biotech industry. This includes top management, marketing, sales, business development, licensing, regulatory affairs and product life cycle management. His background includes a broad international network in several pharmaceutical and biotech companies in Europe, US and key emerging markets. He has experience working with investors and the financial community including the IPO listing of Pronova BioPharma in 2007. He Founded in 2010 Birk Venture.
Co-investor and external partner
Per-Oluf has 27 years experience in the Pharmaceutical and Biotech industry. He has Top management experience from both small and large organization within Pfizer e.g. Country Manager in Norway /Denmark and Italy, Regional Executive Director for Central and Eastern European Region. Last year he has held the position as CEO of Pronova BioPharma AS.
His experience covers all areas of the business from R&D to running a large organization in one of Europe’s biggest market.
Svanhild og Arne Musts Fond
Take the long view – It takes hard work and patience to build great companies. There are no short cuts to success. It takes time for markets to emerge and organisations to develop and mature.
Partnership is fundamental – Strong partnership and involvement with people, organisations and stakeholders is essential to succeed with a company.
Enjoy the journey – The journey to success will not be smooth and easy. To handle the ups and downs, it is important to work with people that share the same values, business ideas and trust each other. It very often comes down to chemistry between people and having fun working together.
BerGenBio is a privately-held biotech company built on proprietary screening technology used for the research and pre-clinical development of novel drug targets and associated biomarkers. Based on this novel technology the company is developing first in class therapeutics for the treatment of cancer, with lead programs against metastatic drug resistant solid tumors, EMT and drug resistance. The lead candidate has entered clinical phase 1.
Birk Venture made the first investment in 2011 and has one seat in the board of Directors of the company.
Nordic Nanovector AS is a privately held company established in 2009. The company develops novel anticancer therapeutics based on The Norwegian Radium Hospital and Nordic Nanovector's own innovative research on tumor targeted antibody based nanovector.
By applying a beta-particle emitting radionuclide conjugated to a tumor seeking carrier, malignant metastasized tumors can be irradiated with minimal damage to nearby healthy normal tissue. This technology aims to prolong survival and improve the quality of life of people who suffer from hematologic cancer in particular non-Hodgkin Lymphoma.
Compared with current antibody based therapies on non-Hodgkin Lymphoma which uses the antigen CD20 as the target, Nordic Nanovector' lead compound Betalutin targets the CD37 antigen that is expressed on almost all B-cell in non-Hodgkin Lymphoma. Thus, the large number of patients who eventually fail CD20 directed therapies could benefit from CD37 directed therapies.
The leading candidate, Betalutin has entered clinical phase 1.
Birk Venture made the first investment in the company in 2010.
APIM Therapeutics is a biotechnology company dedicated to the development of novel-cancer agents targeting DNA repair and cell cycle control. The Company is developing a pipeline of peptide compounds that inhibit PCNA-dependent DNA repair in cancer cells. The lead compound, ATX-101, has shown proof-of-concept in multiple preclinical in vitro and in vivo cancer models.
Birk Venture made the first investment in 2011 and has one seat in the board of Directors of the company.
Targovax was established in 2010 and is developing peptide based active immunotherapy in the form of cancer vaccines. The technology is based on extensive research from Radiumhospitalet and Norsk Hydro. The lead candidate TG01 has initiated phase 1/2 clinical trial in resectable pancreas cancer.
Birk Venture made the first investment in 2012 and has one seat in the board of Directors of the company.
Nextera is a biotechnology company based on a proprietary new phage display technology. The company develops pharmaceuticals targeting autoimmune diseases through unique new drug targets. Nextera utilizes the pVII capsid protein of filamentous bacteriophages as a scaffold for display of peptides and proteins. The technology fosters easy display of two different proteins on the very same phage particle, thus gaining new functionality to existing phage display systems. Nextera is based on technology from the internationally renowned group of Professor Inger Sandlie at the University of Oslo. Sandlie’s group is one of the pioneers in the field of antibody engineering with articles in highly rated journals such as Nature, Nature reviews in drug discovery and PNAS etc. The company has the vision to be a leading source of new drug targets and drug candidates for autoimmune diseases.
Birk Venture made the first investment in 2010 and has two seats in the board of the Directors of the company.
Algeta is an oncology company developing treatments for bone metastases and disseminated tumor types. The company's lead product Alpharadin is targeting bone metastases which occur frequently in major cancers including hormone-refractory prostate cancer, breast, lung, kidney and thyroid. The treatment of bone metastases represents an area of high unmet medical need.
Algeta's pipeline is built on world-leading, proprietary technology. Algeta is developing new, targeted cancer alpha-pharmaceuticals that harness the unique characteristics of alpha particle emitters to destroy cancer cells. Alpha particle emitters are potent, well tolerated and convenient to use.
The first investment from Birk Venture/Investment was made in 2007.
Cortendo AB is a biopharmaceutical company headquartered in Göteborg, Sweden. Its stock is publicly traded on the NOTC-A-list (OTC) in Norway. Cortendo is a pioneer in the field of cortisol inhibition and has completed early clinical trials in patients with Type 2 diabetes. The lead drug candidate NormoCort™, the 2S,4R-enantiomer of ketoconazole, is expected to enter into a Phase 3 study during Q4’2013 for Cushing’s Syndrome. The company’s strategy is to focus its resources to opportunities where the path to commercialization or partnership is clear and relatively near-term. Strategically, Cortendo’s business model is to commercialize relevant opportunities in the United States while partnering its assets ex-US. Backed by a highly experienced leadership team Cortendo has plans to continue to implement its pipeline expansion efforts in osteoarthritis and diabetes, as well as other near term revenue opportunities.
PCI Biotech® (*exited) has developed a unique and patented photochemical drug delivery technology for use in cancer therapy and other diseases.
PCI (PhotoChemical Internalisation) is a technology for light-directed drug delivery by triggered endosomal release and was developed to introduce therapeutic molecules in a biologically active form specifically into diseased cells. The company’s lead candidate drug is the proprietary photosensitiser Amphinex®.
PCI Biotech® has an ongoing clinical phase I/II study at University College Hospital in London. In this study Amphinex® is combined with the cytotoxic agent bleomycin. The study is primarily enrolling patients with Head & Neck cancer, a disease with local control issues that the PCI technology could potentially contribute to solve.
The company has initiated pre-clinical trials for the use of PCI in the treatment of bladder cancer. Bladder cancer has the highest average per-patient life-time cost of all cancers, mainly due to a high recurrence rate. The currently used chemotherapeutic drugs have limited effect on recurrence and progression, and there is a large unmet therapeutic need. Screening studies indicate that the effect of several of these chemotherapeutic drugs may be significantly enhanced by PCI. The pre-clinical trials will be performed at Radboud University Nijmegen, The Netherlands and at The Norwegian University of Science and Technology (NTNU) in Trondheim, Norway.
PCI Biotech® collaborates closely with The Norwegian Radium Hospital in Oslo, Norway and receives substantial funding on several projects from both the Norwegian Research Council and the EU. The company has an extensive international collaboration network with recognised drug delivery expert groups.
Targovax announces today that the clinical trial with TG01 in operable pancreatic cancer now has reached Phase IIa. Promising Phase I-results triggered a 12.5 MNOK milestone, committed in 2012, from current owners. TG01, a RAS mutation-targeted medicine, is used in combination with chemotherapy. The trial is expanding from OUS Radiumhospitalet, the Clinical Trials Unit, to also include two sites in UK, namely The Christie NHS Foundation Trust in Manchester, and The Clatterbridge Cancer Centre NHS Foundation Trust in Liverpool.